Track 04 of 9
Parkinson’s & Movement Disorders
Advanced therapies, DBS, GBA-targeted treatments.
Movement disorders are entering a precision-medicine era, with genetically stratified trials in GBA1 (LTI-291/venglustat lessons, BIA 28-6156) and LRRK2 (BIIB122/DNL151) carriers redefining trial design. GCNN 2027 will cover the expanding device-aided therapy landscape — subcutaneous levodopa (ND0612, ABBV-951/foslevodopa-foscarbidopa), adaptive closed-loop DBS, and MRI-guided focused ultrasound subthalamotomy and pallidotomy. The track also addresses alpha-synuclein seed amplification assays as a biological diagnostic, prasinezumab and other anti-aggregation programs, and the emerging GLP-1 signal in Parkinson’s (exenatide LixiPark readout).
Focus areas
- GBA1 and LRRK2 stratified trials: ambroxol, BIIB122, BIA 28-6156
- Subcutaneous levodopa pumps: ND0612, foslevodopa-foscarbidopa
- Adaptive closed-loop DBS and directional leads
- MRI-guided focused ultrasound: subthalamotomy, pallidotomy, tremor
- Alpha-synuclein seed amplification assays as a biological diagnostic
- Disease modification: prasinezumab, GLP-1 agonists (exenatide, lixisenatide)
- Atypical parkinsonism: PSP, MSA tau and synuclein programs